Crixivan
(Indinavir sulfate)ApprovedSmall molecule
Indinavir sulfate is used to treat HIV (human immunodeficiency virus) infection by helping to slow or stop the virus from multiplying in the body. It is typically used as part of a combination therapy with other HIV medications.[2] Crixivan is currently approved and in use across 4 indications[4].[1]
Crixivan is one of 111 small molecule programs targeting Hemophilia. It is currently in Approved.
4
Indications
80
Total Trials
0
Active Trials
110
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1Crixivan
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Dexilant
TakedaPreclinical
Niclocide
BayerPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Valium
Akero TherapeuticsPreclinical
Clomid
FerringPreclinical
Barhemsys
Tibotec Pharmaceuticals, IrelandPreclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Lotemax
PPharmos
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Effectiveness23 trials
The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000850·108 enrolled
Show 20 more trials
Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000901·24 enrolled
Drug11 trials
Show 8 more trials
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001095·94 enrolled
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000912·475 enrolled
HIV9 trials
Show 6 more trials
A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001086·300 enrolled
HIV infection6 trials
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000870·200 enrolled
Show 3 more trials
A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled
Treatment5 trials
Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000903·444 enrolled
A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001084·500 enrolled
The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000861·1,900 enrolled
Show 2 more trials
Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00012519·29 enrolled
26 more indications
Tolerance1 trial
Interaction1 trial
Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00039975·32 enrolled
Hemophilia1 trial
HIV-11 trial
Pregnant Women1 trial
Immune System1 trial
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001119·288 enrolled
Randomized1 trial
HIV-1 infection1 trial
Children1 trial
Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001083·240 enrolled
Radiation Therapy1 trial
Mycobacterium Avium Complex1 trial
Drug Therapy1 trial
Drug Interactions1 trial
HIV-Infected Individuals1 trial
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000859·1,300 enrolled
Adult1 trial
Safety and Efficacy1 trial
Treatment Failure1 trial
Progesterone1 trial
LAM1 trial
Women1 trial
Drug Resistance1 trial
Interleukin1 trial
Transplantation1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Apr 19, 2000
CRIXIVAN
NDA NDA020685
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Crixivan drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Indinavir sulfate. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details